The relation between serum and synovial fluid (SF) C reactive protein (CRP) concentrations was investigated in a variety of arthritides, including rheumatoid arthritis (RA), psoriatic arthritis, reactive arthritis, and osteoarthritis. SF CRP levels were significantly reduced compared with serum levels in the inflammatory arthritides, but there was good correlation between serum and SF values. SF CRP values were all at the lower limit of the detectable range in osteoarthritis. In patients with RA or psoriatic arthritis followed up serially through an exacerbation of arthritis, changes in SF CRP reflected closely changes in serum CRP. In patients with RA SF/serum ratios of proteins of different molecular weight were used to derive a regression equation between SF/serum ratio and molecular mass. SF/serum values for CRP were significantly less than predicted from its molecular weight, suggesting that CRP is either being selectively bound in synovium or specifically consumed in SF and may be playing an important part in the inflammatory process in RA.
C reactive protein (CRP) is the classical acute phase reactant, circulating concentrations of which may increase up to 1000-fold in response to a wide variety of tissue damaging processes.' Raised levels occur in certain forms of inflammatory arthropathy, including rheumatoid arthritis (RA) and psoriatic arthritis.3 In RA serum CRP levels correlate well with disease activity and are a useful aid in the clinical management of this condition. 2 4 CRP is produced exclusively in the liver; control of synthesis being mediated by a family of polypeptides known as interleukin 1. The CRP molecule has calcium dependent binding sites for phosphorylcholine residues5 6 conservation through evolution of the structure and ligand binding specificity of CRP suggests that it has an important function, which is presumably beneficial. In contrast, there is some evidence to suggest that CRP may, in certain circumstances, promote or enhance inflammation through activation of the complement system,'2 13 and intra-articular injection of CRP may exacerbate inflammation induced by poly-D-lysine in rabbit knee joints.'4 We undertook to investigate the relation between CRP concentrations in serum and SF in RA, a number of other inflammatory arthritides, and in osteoarthritis in order to attempt to determine whether this protein is subserving a major role in the inflammatory process within the joint.
Patients and methods
Serum samples and SF specimens aspirated from one or both knee joints immediately after venepuncture were obtained from patients with different arthropathies (Table 1) . Samples from 17 patients diagnosed as having RA according to the criteria of the American Rheumatism Association '5 were studied, three patients being followed up serially from three to seven months, allowing collection of a total of 49 pairs of samples. Five patients with psoriatic 721 722 Rowe, Sheldon, Riches, Keat tration and SF/serum CRP ratio in any of the inflammatory arthritides studied. The same samples from patients with RA were used to obtain SF/ serum ratios of proteins of different molecular weight (a, acid glycoprotein, albumin, transferrin, caeruloplasmin, and a2 macroglobulin; relative molecular mass 40 000, 66 290, 76 800, 132 000, and 725 000 daltons respectively) and thus derive a regression equation between SF/serum ratio and relative molecular mass (protein ratio= -0-2x1og1(, relative molecular mass+1-61; multiple R=0.65) (Fig. 4) . SF/serum values for CRP were significantly less than predicted from its molecular weight (105 500 daltons) (t test, p<0O0001). It was also found that SF/serum values for CRP were significantly less than those for transferrin or caeruloplasmin (Mann-Whitney U test, p<0 0001), the two proteins of closest molecular weight to CRP that were studied. Discussion The results of this study confirm previous reports of raised serum CRP concentrations in RA2 and psoriatic arthritis,3 and show that raised levels may occur in patients with reactive arthritis secondary to non-gonococcal urethritis. We have demonstrated that SF CRP concentrations in these inflammatory arthritides are significantly reduced compared with those in serum, but in each condition there is a good correlation between serum and SF values. In a few cases with RA, and one with acute gout, a considerable difference between SF CRP values was noted in samples obtained at the same time from each knee. Prospective objective studies of the degree of inflammation of each joint were not performed in this study, but it would be of interest in these circumstances to know which was the more severely affected joint clinically. The low SF CRP values in patients with osteoarthritis are not unexpected in view of the generally low serum CRP concentrations in this condition.
Serial samples were not available from patients with reactive arthritis, but studies on patients followed up serially through an exacerbation of RA or psoriatic arthritis indicate that SF CRP values mirror closely serum levels-best demonstrated in a patient with psoriatic arthritis with essentially monoarticular disease affecting the knee. The half life of CRP is rapid (3-7 hours)'7 18 compared with most other plasma proteins, and although patients were not investigated more frequently than weekly, there was no evidence in our study of a time lag before SF CRP concentration reflected a change in serum level, or evidence of relative accumulation of CRP within the joint.
Many plasma proteins are present in reduced concentrations in SF, '9 20) which CRP may be involved in promoting inflammation or facilitating processes of resolution and repair, they suggest that CRP may be playing an important part in the inflammatory process in RA. Further studies of CRP in RA and other forms of inflammatory arthritis would therefore be of considerable interest and potential importance in the further understanding of these conditions.
